Pertuzumab Market Trends Analysis, Growth Insights, Size Estimation, Key Companies Profile, Share Analysis and Global Market Statistics By 2027
SEATTLE, April 12, 2021, (PHARMIWEB) — Pertuzumab is a recombinant monoclonal antibody, which acts as an antineoplastic agent that targets the human epidermal growth factor receptor 2 protein known as HER2. This drug is capable of blocking signaling pathways, which results in cell growth arrest and apoptosis (cell destruction). This impedes the proliferation of human tumor cells. Pertuzumab aids in the treatment of HER2 associated breast cancer and was developed by Genentech, Inc., a subsidiary of F. Hoffmann-La Roche AG. It was first approved by the U.S. Food and Drug Administration in 2012.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/2256
Pertuzumab Market– Drivers
An increasing number of clinical trials are conducted for use of pertuzumab in combination with other drugs for the treatment of breast cancer. For instance, Helsinki University Central Hospital is undergoing phase III clinical study for adjuvant trastuzumab, pertuzumab, and docetaxel in the treatment of early HER2 positive breast cancer. The study was started in December 2015 and is estimated to be completed by June 2023.
Moreover, rising number of drug approvals is expected to drive the global pertuzumab market growth. For instance, in December 2017, the U.S. Food and Drug Administration (U.S FDA) granted approval to PERJETA, a pertuzumab produced by Genentech, Inc., for its application in combination with trastuzumab and chemotherapy as adjuvant treatment for patients suffering from HER2-positive early breast cancer.
Furthermore, the development of novel anticancer drug delivery technologies is expected to drive the market growth over the forecast period. For instance, in July 2018, Gentech, Inc., in partnership with Halozyme Therapeutics, Inc., utilized proprietary ENHANZE drug-delivery technology of Halozyme Therapeutics, Inc., for subcutaneous administration of fixed-dose combination of pertuzumab (PERJETA) and trastuzumab (Herceptin). This study is under clinical phase III trial. ENHANZE technology helps in reducing the need for multiple injections and reduces the time taken for administration of the drug.
Pertuzumab Market– Restraints
The increasing cost of anticancer drugs is expected to be a major factor restraining the market growth. For instance, in June 2017, The Scottish Medicines Consortium (SMC) denied access to pertuzumab in England, which was available via the Cancer Drugs Fund (CDF) in Europe. The SMC rejected the drug, as the treatment of HER2 positive breast cancer using pertuzumab in combination with trastuzumab and docetaxel was not cost-effective.
Moreover, according to a study published in the journal Oncology, September 2015, although the use of pertuzumab with docetaxel and trastuzumab as first-line therapy for HER2 positive breast cancer yields a substantial survival benefit, this therapy is not cost-effective in the U.S. Also, according to the same source, the cost of treating HER2 positive breast cancer with pertuzumab and other drugs is US$ 509,845 and that with only docetaxel and trastuzumab is US$ 135,092.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2256
Pertuzumab Market– Regional Analysis
On the basis of region, the global pertuzumab market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global pertuzumab market. This is attributed to the rising prevalence of breast cancer among women in the U.S. For instance, according to American Cancer Society 2017, in 2017, around 52,710 new cases of invasive breast cancer were diagnosed among women in the U.S. and in the same year, around 40,610 women were estimated to die due to breast cancer in the U.S.
Asia Pacific is expected to witness significant growth in the global pertuzumab market. This is attributed to rising awareness about breast cancer and its management in the region. For instance, in November 2016, India launched National Cancer Screening Program to increase awareness and early detection of breast cancer. This main aim of the program is to offer mechanism for effective screening and management of common cancers.
Pertuzumab Market – Competitive Landscape
Key players operating in the global pertuzumab market include Halozyme Therapeutics, Inc. and F. Hoffmann-La Roche Ltd.
Pertuzumab Market Taxonomy:
- By Indication
- Early Breast Cancer
- Metastatic Breast Cancer
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Asia Pacific
- Latin America
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire